Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …

Most patients (pts) with CML in chronic phase treated with imatinib achieve a major
cytogenetic (CG) remission, and increasing numbers of pts are achieving molecular …

Abstract Imatinib mesylate (STI571), a specific Bcr-Abl inhibitor, has shown a potent
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …

Editorials and Perspectives haematologica| 2013; 98 (8) 1169 four years. These results
were confirmed in the multicenter STop IMatinib (STIM) study. 14 The initial analysis …

In CML patients treated with allogeneic stem cell transplantation, achievement of molecular
remission (MR), defined as undetectable BCR–ABL transcripts by nested RT-PCR, is …

Real‐time quantitative reverse transcription‐polymerase chain reaction (Q‐RT‐PCR) is
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …

Introduction. Discontinuation (D/C) of Imatinib or other TKIs in Chronic Myeloid Leukemia
(CML) represents an important issue in the management of this disease. It is generally …

Abstract Abstract 783 FN2 Introduction: The advent of second generation tyrosine kinase
inhibitors (TKI) in the front line treatment setting of chronic myeloid leukemia (CML) has …

Imatinib is effective for the treatment of chronic myeloid leukemia (CML). However even
undetectable BCR‐ABL1 by Q‐RT‐PCR does not equate to eradication of the disease …

18013 Background: Chronic myeloid leukemia (CML) landscape has radically changed
since treatment with imatinib. As the majority of CML patients (pts) treated with imatinib …